Ravi Vij

The paper integrates coding and noncoding genome annotations to improve transcriptomic analysis, identifying clinically relevant noncoding RNAs in multiple myeloma.

The paper defines the RNA modification landscape in multiple myeloma, identifying m6A modifications on lncRNAs and showing METTL3-dependent regulation of NEAT1 affecting MM cell survival.

This paper develops a high-throughput single-cell proteomic method for PBMCs, achieving 660 cells per day with 750 protein identifications per cell and identifying low-frequency cell types.

The paper characterizes immune microenvironment dysregulation in multiple myeloma using single-cell data and links it to disease progression and patient outcomes.

This study identifies LINC01432 as a lncRNA that binds to CELF2 and inhibits apoptosis in multiple myeloma, contributing to short progression-free survival to standard therapy.

This study uses longitudinal multi-omic profiling to identify immune escape mechanisms and predictors of response in multiple myeloma.

This study uses linked-read sequencing to phase somatic mutations in multiple myeloma, extending haplotype blocks and revealing phasing patterns in key mutated genes.

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.